New drugs for acute kidney injury
- PMID: 35999470
- PMCID: PMC9705447
- DOI: 10.1007/s00134-022-06859-y
New drugs for acute kidney injury
Conflict of interest statement
PP received speaker honoraria from Baxter and advisory board consulting reimbursement from AM-Pharma, EBI, Sphingotec, Adrenomed, 4Teen4. PM received Trial Steering Committee consultancy payments from AM-Pharma. Other consultancy payments: FAST Biomedical, Novartis, Renibus Therapeutics. MO received speaker honoraria from Fresenius Medical Care, Biomerieux, Baxter and Gilead, and research funding from Fresenius Medical Care, Biomerieux, Baxter and LaJolla Pharma and advisory board consultancy reimbursements from AM-Pharma.
Figures
References
-
- KDIGO KDIGO clinical practice guideline for acute kidney injury. Kidney International Supplements. KDIGO AKI Work Group. 2012;2:1–138.
-
- Ostermann M, Zarbock A, Goldstein S, Kashani K, Macedo E, Murugan R, et al. Recommendations on acute kidney injury biomarkers from the acute disease quality initiative consensus conference: a consensus statement. JAMA Netw Open. 2020;3(10):e2019209. doi: 10.1001/jamanetworkopen.2020.19209. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
